Cerenome Inc (CNSY) Stock Price, Quote & News

andre82 Aug. 19 at 1:55 PM

$CNSY #Zeronome. Dont forget the 100 million dollar offering is ready to go. They will run out of cash yet again in less than 3 months. Outstanding share count is about to explode! Shorts are in a safe haven here. Facts only please. https://www.sec.gov/Archives/edgar/data/1095981/000119312526252119/d138711ds3.htm

0 · Reply

laaarsas Aug. 19 at 1:38 PM

$CNSY Why the recent drop?

1 · Reply

Marketmoverjoe Aug. 18 at 8:18 PM

$CNSY Oh, Gee. down another 4% today.

0 · Reply

andre82 Aug. 18 at 12:50 PM

$CNSY Smart folks identify the pattern. You can profit on this! Join us and sell short ahead of the offering. Theyre burning $9M per quarter and will run out of cash in < 3 months. 🔥🩸

0 · Reply

joka2189 Aug. 18 at 11:29 AM

$CNSY Increased yesterday 3.03 bending myself a bit but in line with where i want my energy stored at this time. Did also 3.80-4.20. Its being accumulated absolutely no doubt. Flushes are being bought up instantly and balancing out with evident spikes in flow and volatility on the weeks of the drops below range. Asks have been thinned to point of non existence it feels. Question is for how much longer and that 3.33 acting as temporary support and res here feels pertinent as it works under and above. Lots got flushed again as did off the 5.18-4.10 drop on weekly. Weekly BBs lower band and upper band angle and movement over this period implies huge volatility coming as cannot be contained in range.

2 · Reply

nopennys Aug. 18 at 7:41 AM

$CNSY Aka PSTV Oh they are saving human life. True. Let the big pharma out some money as well.. they won't.. That's why they have retail. Strategy for the previous years, strategy for the years to come: 👇🏼

0 · Reply

vaccigen Aug. 18 at 12:40 AM

$CNSY going down the drain already. ready to issue more shares. dasholes.

0 · Reply

Marketmoverjoe Aug. 17 at 9:26 PM

$CNSY Bring in the SEC on these crooks. enough already. If I'm going down with my investment, these crooks should be in jail

0 · Reply

MrWicks Aug. 17 at 9:22 PM

$CNSY Tests….

0 · Reply

brokenrecordcordcord Aug. 17 at 8:39 PM

$CNSY You guys really need to start a petition, or something, to get your CEO the f outta there. #HedrickOUT

0 · Reply

Cerenome Reports Second Quarter 2026 Financial Results and Business Update

Aug 14, 2026, 7:00 AM EDT - 5 days ago

Cerenome Quarterly report: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 5 days ago

Cerenome Earnings release: Q2 2026

Aug 13, 2026, 7:30 AM EDT - 6 days ago

Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives

Jul 31, 2026, 8:30 AM EDT - 19 days ago

Cerenome Launches as an Integrated CNS Oncology Company

Jul 28, 2026, 7:30 AM EDT - 22 days ago

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

Jul 21, 2026, 7:30 AM EDT - 4 weeks ago

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Jul 16, 2026, 7:30 AM EDT - 4 weeks ago

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

Jul 14, 2026, 7:30 AM EDT - 5 weeks ago

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

Jun 30, 2026, 7:30 AM EDT - 7 weeks ago

Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding

Jun 25, 2026, 7:30 AM EDT - 7 weeks ago

Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Jun 23, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics to Provide Business Update Call on June 30, 2026

Jun 4, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

May 26, 2026, 7:30 AM EDT - 3 months ago

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

May 19, 2026, 7:30 AM EDT - 3 months ago

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

May 15, 2026, 4:05 PM EDT - 3 months ago

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

May 8, 2026, 7:30 AM EDT - 3 months ago

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

May 7, 2026, 7:30 AM EDT - 3 months ago

Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic

Apr 28, 2026, 7:30 AM EDT - 4 months ago

Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Apr 23, 2026, 7:30 AM EDT - 4 months ago

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

Apr 22, 2026, 4:30 PM EDT - 4 months ago

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Apr 21, 2026, 7:30 AM EDT - 4 months ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 15, 2026, 7:30 AM EDT - 4 months ago

Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

Apr 9, 2026, 7:30 AM EDT - 4 months ago

Plus Therapeutics Appoints Eric J. Daniels, M.D.

Apr 8, 2026, 7:30 AM EDT - 4 months ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

Apr 7, 2026, 7:30 AM EDT - 4 months ago

Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

Apr 2, 2026, 7:30 AM EDT - 4 months ago

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

Mar 26, 2026, 7:30 AM EDT - 5 months ago

Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

Mar 19, 2026, 7:30 AM EDT - 5 months ago

Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

Mar 12, 2026, 4:15 PM EDT - 5 months ago

Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

Feb 25, 2026, 7:30 AM EST - 6 months ago

Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

Jan 21, 2026, 4:15 PM EST - 7 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

Jan 14, 2026, 8:00 AM EST - 7 months ago

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

Jan 8, 2026, 7:30 AM EST - 7 months ago

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

Dec 11, 2025, 7:30 AM EST - 8 months ago

Plus Therapeutics Expands CNSide Assay Platform to State of California

Dec 9, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

Dec 4, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Dec 1, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Nov 24, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

Nov 20, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Nov 17, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Nov 6, 2025, 7:30 AM EST - 10 months ago

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Oct 30, 2025, 4:15 PM EDT - 10 months ago

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

Oct 21, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Sep 25, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Sep 22, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Sep 18, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Sep 2, 2025, 4:15 PM EDT - 1 year ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Aug 18, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Aug 15, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Aug 14, 2025, 4:15 PM EDT - 1 year ago

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

andre82 Aug. 19 at 1:55 PM

0 · Reply

laaarsas Aug. 19 at 1:38 PM

$CNSY Why the recent drop?

1 · Reply

Marketmoverjoe Aug. 18 at 8:18 PM

$CNSY Oh, Gee. down another 4% today.

0 · Reply

andre82 Aug. 18 at 12:50 PM

$CNSY Smart folks identify the pattern. You can profit on this! Join us and sell short ahead of the offering. Theyre burning $9M per quarter and will run out of cash in < 3 months. 🔥🩸

0 · Reply

joka2189 Aug. 18 at 11:29 AM

2 · Reply

nopennys Aug. 18 at 7:41 AM

0 · Reply

vaccigen Aug. 18 at 12:40 AM

$CNSY going down the drain already. ready to issue more shares. dasholes.

0 · Reply

Marketmoverjoe Aug. 17 at 9:26 PM

$CNSY Bring in the SEC on these crooks. enough already. If I'm going down with my investment, these crooks should be in jail

0 · Reply

MrWicks Aug. 17 at 9:22 PM

$CNSY Tests….

0 · Reply

brokenrecordcordcord Aug. 17 at 8:39 PM

$CNSY You guys really need to start a petition, or something, to get your CEO the f outta there. #HedrickOUT

0 · Reply

JimmyOcarri Aug. 17 at 7:47 PM

$ICU $NCEL $LBGJ $RNAZ $CNSY shot

0 · Reply

The_Gambl3r Aug. 17 at 6:39 PM

$CNSY https://youtu.be/Ogqv6CtBfbE?si=_VBPhKP3ukQXmZl6

0 · Reply

MrWicks Aug. 17 at 6:19 PM

$CNSY

0 · Reply

BioHunter1 Aug. 17 at 5:01 PM

$CNSY You guys got mad at me and ignored me! Well, today SP is the proof that i was telling it the way it is, TRASH, GARBAGE, MONEY PIT…. POS company

0 · Reply

andre82 Aug. 17 at 3:01 PM

$CNSY Any time you see a company try to sneak a -$9 million dollar quarter in on a friday afternoon, you know theyre trying to fvck you over. Stay smart. Offering is next, do not fall for any traps.

0 · Reply

The_Gambl3r Aug. 17 at 2:08 PM

$CNSY $NUWE Red Green Show anyone 😅

1 · Reply

andre82 Aug. 17 at 2:01 PM

$CNSY Just a reminder, if youre going to come at the king 🤴 you better not miss! Offering hasnt even happened yet. Get ready

0 · Reply

andre82 Aug. 17 at 1:55 PM

$IAUX $CNSY both hitting 2.00 dollars in a short matter of time. One big long position, one big short position. LFG!

0 · Reply

Heywood_Jablomi Aug. 17 at 1:38 PM

$CNSY

0 · Reply

andre82 Aug. 17 at 1:18 PM

$CNSY Anytime you see the Mo Moron Collective pumping a ticker, you know you should be shorting! This is what one would call "free money short". See you at 2 dollars with a 9 million dollar per quarter cash burn 🔥 🔥 🔥

0 · Reply

Investor1862 Aug. 17 at 10:36 AM

$CNSY piece of shit. Back below one dollar soon, another reverse split next year. Rinse and repeat.

1 · Reply

flywithfitz81 Aug. 16 at 6:05 AM

$CNSY Surefire investment. Sure to make you wish you fired your financial advisor.

0 · Reply

Market Cap	22.03M
Revenue (ttm)	5.21M
Net Income (ttm)	-22.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-429.75%
Debt to Equity Ratio	0.06

Volume	92,500
Avg Vol	154,550
Day's Range	N/A - N/A
Shares Out	6.88M
Stochastic %K	8%
Beta	1.43
Analysts	Sell
Price Target	$34.50